Key Takeaways
- Profit over revenue, by design: Dollar bottom-line growth hit 18.2% YoY while revenue stayed modest; management is explicit that it will trade revenue for margin when demand is soft.
- Margin expansion was partly structural: EBITDA rose 200 bps QoQ, with a 1.4% offshore mix shift likely to stick, but leave utilization and some efficiencies will reverse next quarter.
- TMT is a deliberate drag: The vertical is now less than 10% of revenue and management has told teams to look beyond it; flat performance at best is the working assumption.
- AI classification is intentionally conservative: Only net-new and new-scope deals count as AI-influenced, a discipline meant to avoid the "100% digital overnight" inflation that muddied past cycles.
- What to watch next quarter: Whether volume growth converts to revenue when working days rise, how much of the margin gain is reinvested, and any stabilization in Life Sciences consolidation headwinds.
The Profit-First Posture
- Bottom-line focus is the stated philosophy: Management frames shareholder value as a combination of revenue growth and EBITDA percentage, and in a soft quarter chose to execute for higher margin rather than chase volume.
- Dollar profit growth as the scorecard: The CEO pointed to 18.2% YoY dollar bottom-line growth and challenged analysts to find peers matching it, redirecting the conversation away from revenue growth timelines.
- Revenue resilience with a caveat: Modest revenue performance was supported by healthy offshore volume growth of 3.1%, but mix shift and furlough-related softness moderated the top-line outcome.
- Employee cost fell sharply: Leave provisioning, higher leave utilization (~1% benefit), and a 52-head on-site reduction in Q3 (plus the full-quarter impact of the prior quarter's 90-head cut) drove the decline.
- No revenue guidance given: Management declined to guide on Q4 growth turnaround, stating "we don't give guidance," though hope was expressed for improvement.
Manish Tandon: "I'm a bit old school. I still focus on the bottom line... I will not go in for revenues that don't lead to profitability and margins."
Margin Walk & Sustainability
| Margin driver (QoQ) | Impact | Durability |
|---|---|---|
| Positive forex | +0.7% | Variable |
| Improved offshore effort mix | +1.4% | Structural, likely to stay |
| Leave utilization benefit | +1.0% | One-off, reverses next quarter |
| Other operational efficiencies | +0.7% | Partially one-off |
| Furlough impact | –1.0% | Seasonal |
| Full-quarter ESOP cost | –0.9% | Recurring |
| Net EBITDA expansion | +200 bps |
- Structural vs transient split: The offshore mix shift is the durable gain; management confirmed leave utilization and some operational efficiencies "may go away next quarter."
- Reinvestment intent: The expansion will be partly ploughed back into AI capabilities and sales, so the net margin trajectory depends on how much operating leverage survives that spend.
- Mid-teen margin guidance held: Management maintained the mid-teen target, with the caveat that some improvements should sustain but the endeavour is to invest back.
- Offshoring correlation note: When currency is stable, offshore volume and revenue correlate directly; with significant depreciation, that correlation breaks, complicating volume-to-revenue conversion.
Vertical Health Check
| Vertical | Trend | Commentary |
|---|---|---|
| BFSI | ▲ Secular growth | Strength across Europe, Africa and US; broad-based demand. |
| TMT | ▼ Structural drag | Now less than 10% of revenue; large clients spending on capex/hardware not services, in-sourcing underway, ~30% discounts given to retain business. Management's guess is "on the downside than on the upside." |
| Life Sciences & Healthcare | ▼ Consolidation hit | On the wrong end of consolidation in 1–2 accounts; some Q4 impact expected but not material at company level. |
| Manufacturing / Consumer Services | ▬ Green shoots | Primarily retail exposure; some early positive signals but limited scale. |
- TMT decoupling strategy: The CEO's stated challenge to himself and the team is to deliver double-digit growth despite TMT not delivering; TMT is no longer a "crutch" for growth and the team has been asked to look beyond it.
- Life Sciences headwinds contained: The consolidation-driven drag is account-specific rather than sector-wide, and management expects the residual Q4 impact to stay non-material at the company level.
Manish Tandon: "My challenge now to myself and the team is that can we deliver double-digit growth despite TMT not delivering."
AI: Conservative Classification, Early Build-Out
- AI-influenced order book discipline: Management counts only net-new and new-scope (EN and NN) orders as AI-influenced, deliberately excluding renewals. The CEO stated he does not want AI treated the way digital was, where "suddenly 100% of their revenues became digital overnight." When renewals are excluded, the 20% disclosed figure rises to a "very high number," per management.
- Physical AI lab for a Fortune 50 client: Established a lab focused on large-scale physical simulation and world model development, enabling multi-agent simulation, synthetic data generation and closed-loop training.
- Agentic AI in production: The ZenseAI platform delivered an end-to-end modernization assessment for a financial services client's retail credit processing platform, reverse-engineering 300+ complex mainframe programs and achieving up to 60% faster documentation and 50% faster rule extraction.
- Investment posture: Management continues investing in augmenting capabilities around AI and sales, with some of the margin expansion earmarked for this build-out.
Manish Tandon: "I don't want this to treat AI like people used to treat digital, but suddenly 100% of their revenues became digital overnight. So, I don't want to do that."
The Transformation Context
- Starting point was staff augmentation: The CEO described the inherited company as "a slightly more advanced form of a staff augmentation company," not a stable managed-services platform, requiring margin issues to be fixed before transformation investment could begin.
- Volume growth is real but not yet revenue-visible: Offshore volume grew 3.1% and overall volume 1.7%; on-site declined due to the offshore shift. Management noted that if volume growth sustains alongside higher working days next quarter, revenue should start reflecting it.
- Pipeline strength with conversion uncertainty: The pipeline is described as "fairly strong" but conversion timing is uncertain, and no guidance is offered on when it will translate to reported growth.
- Capital allocation balancing act: The company is actively evaluating M&A situations, mindful of accretion to both revenue and bottom line, while balancing shareholder distributions with cash retained for growth. An interim dividend of INR 2.4 per share was declared.
Manish Tandon: "What we inherited was really a slightly more advanced form of a staff augmentation company, to be very frank."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | Maintain mid-teen margin; some improvements sustain but endeavour is to invest back into AI and sales | Ongoing |
| Double-digit profit growth | Committed to delivering double-digit profit growth going forward | No date |
| TMT decoupling | Deliver double-digit company growth despite TMT staying flat at best | No date |
| Volume-to-revenue conversion | If volume growth sustains with higher working days, revenue should start reflecting it | Q4 FY26 (conditional) |
| Life Sciences headwind | Some impact expected in Q4 but not material at company level | Q4 FY26 |
| M&A | Actively evaluating inorganic opportunities, accretive to revenue and bottom line | No date |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue (USD) | $160.5 million, +2.2% YoY reported, +1.3% YoY constant currency, -1.4% QoQ reported |
| Revenue (INR) | +7.9% YoY, +0.7% QoQ |
| Gross profit | 33.7%, +270 bps QoQ |
| EBITDA | 17.4%, +200 bps QoQ |
| PAT | 13.9%, includes INR 25 crore impact from new labour code changes |
| Diluted EPS | INR 8.7 per share, +9.4% QoQ |
| Profit growth (USD) | +18.2% YoY |
| EPS growth | +24.1% YoY |
| Order book | $180.2 million, +13.6% QoQ, book-to-bill 1.12x |
| Net cash and cash equivalents | $322.4 million, +29.4 million QoQ |
| DSO | 71 days |
| Interim dividend | INR 2.4 per share, 120% of face value |
| Utilization | 83.5%, +60 bps YoY, -130 bps QoQ |
| Voluntary attrition | 9.5%, fourth successive quarter below 10% |
| Gross employee addition | 988 employees |
| Volume growth | 1.7% overall, offshore 3.1%, on-site declined |
| Service lines share of revenue | 69%, +220 bps YoY |
| AI-influenced order book | 20% of new order book (EN and NN only) |
| BFSI revenue growth (YoY reported) | +12.2% |
| Healthcare and Life Sciences revenue growth (YoY reported) | +5.2% |
| Manufacturing and Consumer Services revenue growth (YoY reported) | -2.7% |
| TMT revenue growth (YoY reported) | -11.6% |
| Cloud Infrastructure and Security services growth (YoY reported) | +10.9% |
| Data Engineering and Analytics growth (YoY reported) | +13.1% |
| Enterprise Application services growth (YoY reported) | -3.6% |